What is the unique nature of the Huntington’s Disease?
DOI:
https://doi.org/10.15584/ejcem.2019.2.11Keywords:
CAG repeat, chorea, family system, genetic disease, HD geneAbstract
Introduction. Huntington’s disease is a rare neurodegenerative disease, inherited in an autosomal dominant manner. Every child in the family whose parent is a carrier of the mutant gene has a 50% risk of inheriting the disease. Genetic tests unambiguously confirm whether a person at risk is ill or not. Symptoms include movement, neuropsychiatric and cognitive disorders. Currently, the disease is incurable and there are no effective methods for its treatment.
Aim. The aim is to present information about Huntington’s disease, its inheritance, symptoms and pathologies, as well as to draw attention to its unique impact on patients and their families.
Material and methods. A literature review of the following databases has been conducted: PubMed, Science Direct, EBSCO, Springer Link.
Results. Huntington’s disease, due to the autosomal dominant inheritance, disturbs the whole family system. Over several generations, a family can struggle with the problems of taking care of several patients at the same time, providing children with information about the risk of falling ill, making decisions about genetic testing, and starting a family or having children.
Conclusion. Huntington’s disease is a challenge for healthcare professionals who are not always prepared to solve unique, multi-generational problems in families with Huntington’s disease.
Downloads
References
Barboza LA, Ghisi NC. Evaluating the current state of the art of Huntington disease research: a scientometric analysis. Braz J Med Biol Res. 2018;51(3):e6299.
Wyant KJ, Ridder AJ, Dayalu P. Huntington’s Disease - Update on Treatments. Curr Neurol Neurosci Rep. 2017;17:33.
Nopoulos PC. Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci. 2016;18(1):91–98.
Cardoso IL, Marques V. Trinucleotide repeat diseases - anticipation diseases. J Clin Gen Genomics. 2018;1(1):4-9.
Paulson H. Repeat expansion diseases. Handb Clin Neurol. 2018;147:105–123.
Kay C, Collins JA, Miedzybrodzka Z, et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2016;87(3):282–288.
Tsikritsis D, Elfick A, Downes A. Raman spectroscopy of fibroblast cells from a Huntington's disease patient. Spectrosc Lett. 2016; 49(8):535-54.
Huntington G. On Chorea. Med Surg Rep. 1872; 26: 317–321.
The World Federation of Neurology Research Group on Huntington’s Disease. Presymptomatic Testing for Huntington’s Disease: A World Wide Survey. J Med Genet. 1993; 30:1020–1022.
Huntington’s Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on the HD chromosome. Cell.1993;72:971–983.
Nance MA. Genetic counseling and testing for Huntington's disease: A historical review. Am J Med Genet B Neuropsychiatr Genet. 2017;174(1):75-92.
Potkin KT, Potkin SG. New directions in therapeutics for Huntington disease. Future Neurol. 2018;13(2):101–121.
McCusker EA, Loy CT. Huntington Disease: The Complexities of Making and Disclosing a Clinical Diagnosis After Premanifest Genetic Testing. Tremor Other Hyperkinet Mov. 2017;7:467.
Mahalingam S, Levy LM. Genetics of Huntington Disease. Am J Neuroradiol. 2014;35 (6):1070-1072.
Craufurd D, MacLeod R, Frontali M, et al. Working Group on Genetic Counselling and Testing of the European Huntington's Disease Network (EHDN). Diagnostic genetic testing for Huntington's disease. Pract Neurol. 2015;15(1):80-84.
Ross CA, Aylward EH, Wild EJ, et al. Huntington Disease: Natural History, Biomarkers and Prospects for Therapeutics. Nat Rev Neurol. 2014;10: 204–216.
Reilmann R, Leavitt BR, Ross CA. Diagnostic Criteria for Huntington’s Disease Based on Natural History. Movement Disord. 2014; 29:1335–1341.
Hoffman-Zacharska D. Pacjent rozszerzony – chory i jego rodzina. Konflikty interesów wynikające z możliwości przeprowadzenia badań genetycznych. Med. Wieku Rozw. 2015; 10: 63-73.
Dayalu P, Albin RL. Huntington disease: pathogenesis and treatment. Neurol Clin. 2015; 33(1):101-114.
McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol. 2018;25(1):24-34.
Schiefer J, Werner CJ, Reetz K. Clinical diagnosis and management in early Huntington’s disease: a review. Degener Neurol Neuromuscul Dis. 2015:5 37–50.
Roos RAC. Huntington's disease: a clinical review. Orphanet J Rare Dis. 2010; 5: 40.
Kozak-Putowska D, Iłżecka J, Piskorz J, Wójcik G. Problemy zdrowotne chorych na chorobę Huntingtona i ich wpływ na codzienne funkcjonowanie chorego. Med Og Nauk Zdr. 2016; 22( 2): 94–97.
Solberg OK, Filkuková P, Frich JC, Feragen KJB. Age at Death and Causes of Death in Patients with Huntington Disease in Norway in 1986-2015. J Huntingtons Dis. 2018;7(1):77–86.
Vinther-Jensen T, Larsen IU, Hjermind LE, et al. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease. Orphanet J Rare Dis. 2014;9:114.
Alkabie S, Singh D, Hernandez A, Dumenigo R. The Spectrum of Psychiatric Pathology in a Patient with Genetically Verified Huntington's Disease. Case Rep Psychiatry. 2015;2015:742471.
Ślemp-Dubas H, Tylec A, Michałowska-Marmurowska H, Spychalska K. Choroba Huntingtona zaburzeniem neurologicznym czy psychiatrycznym? Opis przypadku. Psychiatr Pol. 2012; XLVI: 915-922.
Fisher CA, Sewell K, Brown A, Churchyard A. Aggression in Huntington's disease: a systematic review of rates of aggression and treatment methods. J Huntingtons Dis. 2014;3(4):319–332.
Epping EA, Kim JI, Craufurd D, et al. Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data. Am J Psychiatry. 2015;173(2):184–192.
Oosterloo M, Craufurd D, Nijsten H, van Duijn E. Obsessive-Compulsive and Perseverative Behaviors in Huntington's Disease. J Huntingtons Dis. 2019;8(1):1–7.
Sołtan W, Gołębiewska E, Limon J. Choroba Huntingtona — trzy punkty widzenia. Forum Med Rodz. 2011;5(2): 108–114.
McCusker EA, Gunn DG, Epping EA, et al. Unawareness of motor phenoconversion in Huntington disease. Neurology. 2013;81(13):1141–1147.
Wiatr K, Szlachcic WJ, Trzeciak M, Figlerowicz M, Figiel M. Huntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells. Mol Neurobiol. 2018;55(4):3351-3371.
Błaszczyk M, Boczarska-Jedynak M, Rudzińska M. Odmienność kliniczna młodzieńczej postaci choroby Huntingtona. Prz Lek. 2015; 72(7):366-370.
Quigley J. Juvenile Huntington’s Disease: Diagnostic and Treatment Considerations for the Psychiatrist. Curr Psychiatry Rep. 2017;19:9.
Yapijakis C. Huntington Disease: Genetics, Prevention, and Therapy Approaches. Vlamos P, eds. Cham: Springer; 2016:55.
Walker FO. Huntington’s disease. Lancet. 2007; 369:118–218.
Nance M, Paulsen JS, Rosenblatt A, Wheelock V. A Physician’s Guide to the Management of Huntington’s Disease. Huntington’s Disease Society of America 2011.
International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington’s Chorea. Guidelines for the Molecular Genetics Predictive test in Huntington’s Disease. Neurology. 1994; 44: 1533–1536.
Aubeeluck A, Buchanan H. The Huntington’s disease quality of life battery for carers: reliability and validity. Clin Genet. 2007; 71(5): 434–445.
Williams JK, Erwin C, Juhl AR, et al. In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(6):1150–1159.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
